Market price and purchasing advice for a box of fostatinib (fotantinib)

Fostamatinib (Fostamatinib) is an oral spleen tyrosine kinase (Syk) inhibitor, mainly used to treat chronic immune thrombocytopenia (ITP) and other diseases. At present, the drug has not been approved by the National Medical Products Administration of China (NMPA), so it cannot be purchased directly in domestic pharmacies, hospitals and e-commerce platforms. If patients need medicine, they can only obtain medicines from regular overseas pharmacies or pharmaceutical companies through qualified international medicine purchasing services.

In foreign markets, fotantinib is sold by Rigel Pharmaceuticals and its cooperative companies. Currently, the two common specifications are 100mg60 tablets and 150mg60 tablets. It is understood that the European version of the original drug, 100mg60 tablets, is priced at more than 20,000 yuan, while the price of 150mg60 tablets is around 30,000 yuan. Such prices are quite burdensome for most domestic patients, especially when long-term medication is required to maintain efficacy. Financial affordability should be fully assessed before purchasing the drug.

Since fotantinib has not yet been launched in China, patients should pay more attention to channel safety when purchasing the drug. It is recommended to choose an international drug service platform with good reputation and third-party qualification certification for purchasing, to ensure that the source of drugs is regular, the packaging is complete, and the storage conditions meet the standards. Some overseas hospitals or international pharmacies also support prescription purchase and mailing services. Patients can entrust a doctor to issue an English prescription for order placement. Do not purchase medicines through informal platforms or personal transactions to avoid medication risks.

Fortantinib, as a targeted drug that acts on the immune system, may cause side effects such as high blood pressure, elevated liver enzymes, and diarrhea during the course of taking the drug. Therefore, it should be evaluated by a professional hematologist before taking the drug and confirm whether the indications match. During the course of taking the medicine, blood routine, liver and kidney function and other indicators should be reviewed regularly, and the dosage should be adjusted or whether to continue taking the medicine according to the doctor's recommendations. For some patients, fotantinib may be an important treatment option to relieve symptoms of refractory ITP, but it must be used under professional guidance.

Reference materials:https://www.drugs.com/